Brokers Set Expectations for ODTX Q1 Earnings

Odyssey Therapeutics, Inc. (NASDAQ:ODTX) – Equities research analysts at HC Wainwright issued their Q1 2027 earnings estimates for Odyssey Therapeutics in a note issued to investors on Friday, November 6th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings per share of ($1.27) for the quarter. HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Odyssey Therapeutics’ current full-year earnings is ($6.18) per share. HC Wainwright also issued estimates for Odyssey Therapeutics’ Q2 2027 earnings at ($1.29) EPS, Q3 2027 earnings at ($1.29) EPS and Q4 2027 earnings at ($1.28) EPS.

A number of other research analysts also recently commented on the stock. UBS Group initiated coverage on shares of Odyssey Therapeutics in a report on Monday, October 12th. They issued a “buy” rating and a $27.00 price target for the company. Raymond James Financial initiated coverage on Odyssey Therapeutics in a research note on Thursday, October 8th. They set an “outperform” rating and a $42.00 price objective on the stock. JPMorgan Chase & Co. upped their price objective on Odyssey Therapeutics from $26.00 to $29.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Finally, Weiss Ratings initiated coverage on Odyssey Therapeutics in a research note on Tuesday, August 11th. They issued a “sell (d+)” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.67.

Odyssey Therapeutics Price Performance

Shares of NASDAQ:ODTX opened at $19.15 on Monday. The business has a fifty day simple moving average of $21.08. Odyssey Therapeutics has a 52 week low of $15.10 and a 52 week high of $29.05.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Citadel Advisors LLC purchased a new stake in shares of Odyssey Therapeutics in the second quarter valued at $4,162,000. Aberdeen Group plc boosted its stake in shares of Odyssey Therapeutics by 4.7% during the 3rd quarter. Aberdeen Group plc now owns 172,771 shares of the company’s stock worth $3,839,000 after purchasing an additional 7,771 shares during the period. State Street Corp purchased a new position in shares of Odyssey Therapeutics during the 2nd quarter worth about $1,477,000. The Manufacturers Life Insurance Company bought a new position in Odyssey Therapeutics during the 2nd quarter valued at about $601,000. Finally, Russell Investments Group Ltd. bought a new position in Odyssey Therapeutics during the 3rd quarter valued at about $28,000.

About Odyssey Therapeutics

Odyssey Therapeutics is a clinical-stage biotechnology company focused on discovering and developing precision medicines for immune-mediated diseases and cancer. The company combines computational biology, functional genomics, and experimental drug discovery to identify therapies directed at disease-driving biological pathways.

Its research programs are centered primarily on small-molecule medicines and other targeted approaches intended to modulate the immune system or address vulnerabilities in cancer cells.